An Open-Label, Dose-Escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors.

Trial Profile

An Open-Label, Dose-Escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs RG 7167 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jun 2014 Interim results (n=95) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 21 Oct 2013 Planned end date changed from 1 May 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top